Journey Medical 3Q 2026: Revenue $18.97M, EPS ($0.05) — 10-Q Summary
Journey Medical reported 3Q 2026 revenue of $18.97M, up 8% YoY, with net loss narrowing 43% to $1.32M. Emrosi sales grew 84% YoY to $9.0M, while Qbrexza and legacy products saw declines. The company paid $4.1M in vendor settlements.




